AI in Compliance: Automation Without Breaking Audit Trails
The AI hype cycle has reached every industry. CEOs are asking their teams how AI will transform their operations. Vendors are adding "AI-powered" to every product description.
In regulated industries like pharmaceutical manufacturing, the question is more nuanced. It's not whether AI can automate compliance tasks—it clearly can. The question is whether AI can do so while maintaining the data integrity, audit trails, and human oversight that regulators require.
After building AI agents for pharmaceutical compliance at Cohera, I've learned that the answer is yes—but it requires rethinking how we design AI systems.
The Opportunity is Real
Let's be concrete about where AI adds value in pharmaceutical compliance:
Certificate processing: When a supplier sends a Certificate of Analysis (CoA), someone today manually extracts key data points—material specifications, test results, expiry dates—and enters them into quality systems. This takes 15-30 minutes per certificate. AI can extract this data in seconds with high accuracy.
Change impact analysis: When a specification changes, answering "what products are affected?" requires searching through multiple systems and manually tracing relationships. AI can traverse a knowledge graph instantly and identify all affected records.
Document classification: Incoming documents need to be categorized and routed appropriately. AI can classify documents by type and route them to the right queue without human intervention for routine cases.
Expiry monitoring: Tracking when certificates, qualifications, and approvals expire requires monitoring dates across multiple systems. AI agents can monitor continuously and alert proactively.
Natural language queries: "Show me all suppliers with certificates expiring in the next 90 days who supply materials for Product X" is a question that would take hours to answer manually. With AI and a well-structured data model, it takes seconds.
The Regulatory Challenge
Here's where it gets complicated. Regulations like 21 CFR Part 11 and EU GMP Annex 11 weren't written with AI in mind. But the principles they establish still apply:
Attributability: Every action must be attributable to a person. If AI extracts data from a certificate, who is responsible for that extraction? The AI? The person who configured the AI? The person who approved the AI's output?
Data integrity: ALCOA+ principles require that data accurately reflects source documents. If AI misreads a certificate, the resulting record violates data integrity requirements.
Audit trails: Changes must be logged with who made them and why. How do you log an AI's "reasoning" in an audit trail?
Human oversight: Regulators expect human judgment for quality decisions. How much automation is too much?
These aren't hypothetical concerns. Pharmaceutical companies are hesitant to adopt AI precisely because they're unsure how regulators will respond.
Designing AI for Regulated Environments
At Cohera, we've developed an approach that enables AI automation while satisfying regulatory requirements:
1. AI proposes, humans approve
For any action that affects a GxP record, our AI agents propose changes that a human reviews and approves. The AI extracts data from a certificate and presents it for verification. A quality professional reviews the extraction and confirms or corrects it.
This maintains human oversight while dramatically reducing the work. A human reviewing AI-extracted data takes 30 seconds instead of 15 minutes doing manual data entry.
2. Confidence scoring with routing
Not all documents are equally complex. A standard CoA from a known supplier might be extracted with 99% confidence. A handwritten note or unusual format might only reach 60% confidence.
We route based on confidence:
- High confidence → Present for quick verification
- Medium confidence → Highlight uncertain fields for review
- Low confidence → Route to specialist queue for manual processing
This focuses human attention where it's actually needed.
3. Complete audit trails for AI actions
Every AI action is logged with:
- What the AI did
- What inputs it used
- What its confidence level was
- What rules or models governed the decision
- Who configured those rules/models
- The timestamp of the action
- The human who reviewed/approved the output
This creates an audit trail that's actually more complete than traditional manual processes. When an auditor asks "how did this data get into the system?", you can show exactly what happened.
4. Explainable AI decisions
For compliance purposes, "the AI decided" isn't an acceptable answer. Our agents provide explanations:
Certificate Data Extraction Summary:
- Document type: Certificate of Analysis (confidence: 98%)
- Supplier: ACME Chemicals (matched to existing supplier record)
- Material: Sodium Chloride, USP Grade
- Extracted specifications:
- Purity: 99.8% (extracted from page 1, section 3)
- Moisture: 0.02% (extracted from page 1, section 4)
- Heavy metals: <5 ppm (extracted from page 2, section 1)
- Expiry date: 2027-03-15 (extracted from page 1, header)
Review required: Moisture value lower than specification range (0.05% - 0.15%)
This explainability means humans can quickly verify AI work and auditors can understand what happened.
5. Training data governance
AI models are only as good as their training data. In a regulated environment, you need to know:
- What data trained the model
- Who approved that training data
- When the model was last updated
- What the model's performance metrics are
We treat model training as a controlled process with its own documentation and approval requirements.
The Human-AI Partnership
The goal isn't to remove humans from compliance—it's to elevate human work from data entry to decision-making.
Before AI: A quality specialist spends 70% of their time on manual data entry, document retrieval, and routine checks. They're too busy with paperwork to think deeply about quality risks.
After AI: The specialist reviews AI-prepared summaries, focuses attention on exceptions and anomalies, and has time to actually analyze patterns and improve quality systems.
This isn't automation replacing people—it's automation augmenting people to do more valuable work.
Regulatory Reception
How are regulators responding to AI in pharma? The answer is evolving, but some principles are emerging:
The FDA is cautiously supportive. They've issued guidance on AI/ML in medical devices and are developing positions on AI in manufacturing and quality. The theme is that AI can be used if appropriate controls are in place.
Validation expectations persist. AI systems need to be validated for their intended use, just like any other computerized system. This means documenting intended use, verifying performance, and maintaining the validation state.
Human oversight is still required. No regulator is saying "let the AI make quality decisions autonomously." The expectation is human review for any decision that affects product quality or patient safety.
Transparency matters. Regulators want to understand how AI systems work. Black-box AI that can't explain its reasoning will face more scrutiny.
Implementation Advice
If you're considering AI for compliance automation:
Start small. Pick one use case—certificate data extraction is a good one—and prove it works with appropriate controls before expanding.
Involve quality teams early. Don't build AI automation in IT and spring it on quality teams. They need to understand and trust the system.
Document everything. How the AI works, how it was validated, what controls are in place—this documentation will be essential for audits.
Plan for errors. AI will make mistakes. What happens when it does? How are errors detected and corrected? What's the impact on downstream records?
Maintain the human loop. Even as AI capabilities improve, maintain human review for quality-critical decisions. Regulators aren't ready for fully autonomous AI in GxP environments, and neither should you be.
The Future
AI in pharmaceutical compliance is still early. We're in the phase where AI augments human work rather than replacing it. That's appropriate for now.
Over time, as AI systems demonstrate reliability and regulators develop clearer frameworks, more automation will become possible. But the core principle will remain: regulated industries require documented, auditable, human-accountable processes.
The AI systems that succeed in these environments will be the ones that embrace this principle rather than trying to work around it.
At Cohera, we're building AI agents that work the way regulated industries need them to work: transparent, auditable, and always keeping humans in the loop for decisions that matter.
That's not a limitation. It's good engineering for high-stakes environments.